About the Authors
ViroStatics srl, Alghero, Italy
Makerere Medical School, Kampala, Uganda
Infectious Diseases Unit, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Pavia, Italy
Fundación Huesped, Buenos Aires, Argentina
Department of Infectious Diseases, St. Petersburg Health Department, St. Petersburg, Russia
ViroStatics srl, Princeton, New Jersey, United States of America
The study was sponsored by commercial funder ViroStatics srl; FL, DDF and MRS are currently consultants to, employees of and/or hold shares or options in ViroStatics srl. FL is the CEO and President of the Board of ViroStatics srl. Although VS411 is not being commercially developed, there are several patents to protect the VS411 combination product and technology in which FL is an inventor, as follows: “Method of Inhibiting Human Immunodeficiency Virus by combined use of Hydroxyurea, a nucleoside analog, and a protease inhibitor”, USSN 08/812,515 filed Mar 7, 1997. Issued as USPN 6,114,312 on Sep 5, 2000. HU + ddI + protease inhibitor (“Triple Combination Continuation”) Inventors: Julianna Lisziewicz; FL. USSN 09/048,886, WO/1999/048504 filed Mar 26, 1998. Issued as USPN 6,251,874 on June 26, 2001: “Method of Inhibiting Human Immunodeficiency Virus using Hydroxyurea and a Reverse Transcriptase Inhibitor in vivo”. Issued. Method, HU+ddI+Indinavir OR HU + ddI, depending on viral load (“Double or Triple”) Inventors: Julianna Lisziewicz; FL. There are no further patents, products in development or marketed products to declare. This does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials.
Conceived and designed the experiments: FL MRS DDF SAC. Performed the experiments: DDF DB SAC MT. Analyzed the data: FL DDF DB SAC MRS. Wrote the paper: FL DDF MRS. Study Investigators: EK RM PC AR.